Literature DB >> 20689406

High-risk corneal allografts and why they lose their immune privilege.

Jerry Y Niederkorn1.   

Abstract

PURPOSE OF REVIEW: Corneal allografts are routinely performed without HLA typing or systemic immunosuppressive drugs. However, certain conditions create high risks for immune rejection. This review discusses recent insights into the mechanisms that rob the corneal allograft of its immune privilege. RECENT
FINDINGS: Studies in mice have revealed that stimuli that induce new blood vessel growth in the cornea also elicit proliferation of lymph vessels. Lymph vessels facilitate migration of antigen-presenting cells to regional lymph nodes in which they induce alloimmune responses. The presence of blood vessels in the corneal graft bed creates a unique chemokine milieu that stimulates recruitment of sensitized lymphocytes into the corneal allograft. Other data indicate that although corneal allograft survival is closely associated with Foxp3 expression in CD4+CD25+Foxp3+ T regulatory cells (Tregs), reduced expression of Foxp3 in Tregs creates a high risk for graft rejection. Recent evidence indicates that allergic diseases have a profound impact on the immune response and produce a dramatic increase in corneal allograft rejection.
SUMMARY: Understanding the underlying mechanisms that create 'high-risk' hosts may provide important therapeutic targets for restoring immune privilege of corneal allografts and enhancing their survival.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20689406      PMCID: PMC3116237          DOI: 10.1097/ACI.0b013e32833dfa11

Source DB:  PubMed          Journal:  Curr Opin Allergy Clin Immunol        ISSN: 1473-6322


  44 in total

Review 1.  Ocular immune privilege: therapeutic opportunities from an experiment of nature.

Authors:  J Wayne Streilein
Journal:  Nat Rev Immunol       Date:  2003-11       Impact factor: 53.106

2.  Early T cell response to allografts occurring prior to alloantigen priming up-regulates innate-mediated inflammation and graft necrosis.

Authors:  Tarek El-Sawy; Masayoshi Miura; Robert Fairchild
Journal:  Am J Pathol       Date:  2004-07       Impact factor: 4.307

Review 3.  Corneal transplantation: the forgotten graft.

Authors:  A J T George; D F P Larkin
Journal:  Am J Transplant       Date:  2004-05       Impact factor: 8.086

4.  A method for performing full-thickness, orthotopic, penetrating keratoplasty in the mouse.

Authors:  S C She; L P Steahly; E J Moticka
Journal:  Ophthalmic Surg       Date:  1990-11

5.  Sclerokeratitis after keratoplasty in atopy.

Authors:  C J Lyons; J K Dart; W A Aclimandos; S Lightman; R J Buckley
Journal:  Ophthalmology       Date:  1990-06       Impact factor: 12.079

6.  Impaired cell-mediated immunity in mice bearing healthy orthotopic corneal allografts.

Authors:  Y Sonoda; J W Streilein
Journal:  J Immunol       Date:  1993-03-01       Impact factor: 5.422

7.  Viral-induced T helper type 1 responses enhance allergic disease by effects on lung dendritic cells.

Authors:  Martin E Dahl; Karim Dabbagh; Denny Liggitt; Sung Kim; David B Lewis
Journal:  Nat Immunol       Date:  2004-02-15       Impact factor: 25.606

8.  VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment.

Authors:  Claus Cursiefen; Lu Chen; Leonardo P Borges; David Jackson; Jingtai Cao; Czeslaw Radziejewski; Patricia A D'Amore; M Reza Dana; Stanley J Wiegand; J Wayne Streilein
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

9.  Penetrating corneal transplantation in the inbred rat: a new model.

Authors:  K A Williams; D J Coster
Journal:  Invest Ophthalmol Vis Sci       Date:  1985-01       Impact factor: 4.799

10.  The collaborative corneal transplantation studies (CCTS). Effectiveness of histocompatibility matching in high-risk corneal transplantation. The Collaborative Corneal Transplantation Studies Research Group.

Authors: 
Journal:  Arch Ophthalmol       Date:  1992-10
View more
  32 in total

1.  Severing corneal nerves in one eye induces sympathetic loss of immune privilege and promotes rejection of future corneal allografts placed in either eye.

Authors:  K J Paunicka; J Mellon; D Robertson; M Petroll; J R Brown; J Y Niederkorn
Journal:  Am J Transplant       Date:  2015-04-14       Impact factor: 8.086

2.  Effect of sorafenib in a murine high risk penetrating keratoplasty model.

Authors:  Yang Kyung Cho; Eun Young Shin; Hironori Uehara; Balamurali K Ambati
Journal:  Int J Ophthalmol       Date:  2017-06-18       Impact factor: 1.779

Review 3.  Clinical correlates of common corneal neovascular diseases: a literature review.

Authors:  Nizar Saleh Abdelfattah; Mohamed Amgad; Amira A Zayed; Hamdy Salem; Ahmed E Elkhanany; Heba Hussein; Nawal Abd El-Baky
Journal:  Int J Ophthalmol       Date:  2015-02-18       Impact factor: 1.779

Review 4.  Management of high-risk corneal transplantation.

Authors:  Antonio Di Zazzo; Ahmad Kheirkhah; Tulio B Abud; Sunali Goyal; Reza Dana
Journal:  Surv Ophthalmol       Date:  2016-12-22       Impact factor: 6.048

5.  IFN-γ blocks CD4+CD25+ Tregs and abolishes immune privilege of minor histocompatibility mismatched corneal allografts.

Authors:  K Cunnusamy; J Y Niederkorn
Journal:  Am J Transplant       Date:  2013-10-01       Impact factor: 8.086

6.  Presurgical corticosteroid treatment improves corneal transplant survival in mice.

Authors:  Hyun Kyung Kim; Jin A Choi; Hironori Uehara; Xiaohui Zhang; Balamurali K Ambati; Yang Kyung Cho
Journal:  Cornea       Date:  2013-12       Impact factor: 2.651

Review 7.  Islet inflammation in plain sight.

Authors:  M H Abdulreda; P-O Berggren
Journal:  Diabetes Obes Metab       Date:  2013-09       Impact factor: 6.577

8.  Ocular surface rehabilitation: Application of human amniotic membrane in high-risk penetrating keratoplasties.

Authors:  Pho Nguyen; Kelly Rue; Martin Heur; Samuel C Yiu
Journal:  Saudi J Ophthalmol       Date:  2014-07-02

9.  Combined blockade of VEGFR-3 and VLA-1 markedly promotes high-risk corneal transplant survival.

Authors:  Hui Zhang; Sammy Grimaldo; Don Yuen; Lu Chen
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-08-17       Impact factor: 4.799

10.  Vascular Endothelial Growth Factor Receptor 1 morpholino increases graft survival in a murine penetrating keratoplasty model.

Authors:  Yang Kyung Cho; Xiaohui Zhang; Hironori Uehara; Jason R Young; Bonnie Archer; Balamurali Ambati
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-12-19       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.